The Latest Cardiac and Vascular News
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to open vessels and keep them open without the use of permanent implants in the […]
SIOUX FALLS, S.D.–(BUSINESS WIRE)–Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding (NVS)TM, has recently gained FDA approval to move forward with Phase 1 human clinical trials. […]
SIOUX FALLS, S.D.–(BUSINESS WIRE)–Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding (NVS)TM, has recently gained FDA approval to move forward with Phase 1 human clinical trials. […]
